Sharps Technology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STSS research report →
Companysharpstechnology.com
Sharps Technology Inc. , a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications.
- CEO
- Paul Kruger Danner
- IPO
- 2022
- Employees
- 55
- HQ
- Melville, NY, US
Price Chart
Valuation
- Market Cap
- $78.72M
- P/E
- -0.36
- P/S
- 22.29
- P/B
- 0.76
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.14%
- Op Margin
- -450.31%
- Net Margin
- -10497.57%
- ROE
- -166.42%
- ROIC
- -8.89%
Growth & Income
- Revenue
- $204.12K · 0.00%
- Net Income
- $-282,502,126 · -2938.90%
- EPS
- $-11.16 · 99.50%
- Op Income
- $-13,292,480
- FCF YoY
- -136.53%
Performance & Tape
- 52W High
- $18.23
- 52W Low
- $1.42
- 50D MA
- $1.80
- 200D MA
- $3.76
- Beta
- 2.02
- Avg Volume
- 331.29K
Get TickerSpark's AI analysis on STSS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 9, 26 | FalconX Holdings Ltd | other | 461,538 |
| Jan 9, 26 | FalconX Holdings Ltd | sell | 269,321 |
| Jan 9, 26 | FalconX Holdings Ltd | sell | 260,411 |
| Jan 9, 26 | FalconX Holdings Ltd | other | 461,538 |
| Jan 12, 26 | FalconX Holdings Ltd | sell | 47,281 |
| Oct 14, 25 | FalconX Holdings Ltd | other | 0 |
| Oct 14, 25 | FalconX Holdings Ltd | other | 0 |
| Oct 14, 25 | FalconX Holdings Ltd | other | 4,871,192 |
| Oct 14, 25 | FalconX Holdings Ltd | other | 4,871,192 |
| Oct 14, 25 | FalconX Holdings Ltd | other | 461,538 |
Our STSS Coverage
We haven't published any research on STSS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate STSS Report →